Osstem Implant's stock price edged lower due to a management dispute and institutional selling, despite its biotech pipeline.

Following the disclosure of a management dispute lawsuit, the stock faced downward pressure as institutions sold 15,733 shares. Despite IBK Securities' positive outlook with a target price of ₩67,000, the stock closed lower due to short-term uncertainty surrounding the dispute and institutional selling.